HIND
Vyome Holdings Inc.

35,242
Mkt Cap
$23.14M
Volume
19,246.00
52W High
$519.00
52W Low
$4.03
PE Ratio
-0.02
HIND Fundamentals
Price
$4.07
Prev Close
$4.10
Open
$4.03
50D MA
$5.25
Beta
0.01
Avg. Volume
30,575.95
EPS (Annual)
-$1,382.95
P/B
8.94
Rev/Employee
$444,777.78
Loading...
Loading...
News
all
press releases
News Placeholder
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced the final results from an investigator-initiated Phase 2 proof of concept study of VT-1953 topical gel in people with malignant fungating wounds...
Business Wire·9d ago
News Placeholder
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
Vyome Holdings, Inc., (Vyome) (NASDAQ: HIND), a next-generation inflammation-focused company leveraging the USIndia innovation corridor, today announced its financial results and a series of...
Business Wire·29d ago
News Placeholder
Vyome Holdings Announces Results of Annual Shareholder Meeting
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced it held its annual shareholder meeting on October 28, 2025. All 3 Class I directors up for re-election Krishna K. Gupta, Shiladitya Sengupta, and...
Business Wire·1mo ago
News Placeholder
HIND Stock Rallies 70% Pre-Market Today – Find Out Why
In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, Vyome said.
Stocktwits·3mo ago
<
...
1
>

Latest HIND News

View

Advertisement|Remove ads.

Advertisement|Remove ads.